Medical Condition News

RSS

Type 2 diabetes doubles risk of cancer in women

Type 2 adult-onset diabetes causes insulin-like hormones to circulate through the body. A new study finds this has a surprisingly positive effect on reducing the rate of prostate cancer in men, but is bad news for women: Type 2 diabetes may double the risk of female genital and other cancers.

11 Jun 2010

AFREZZA non-inferior to standard therapy insulin lispro in reducing HbA1c levels of Type 1 diabetics

MannKind Corporation today announced that results of a new 16-week trial show that the investigational ultra rapid acting mealtime insulin, AFREZZA™ (insulin human [rDNA origin]) Inhalation Powder, combined with basal insulin, is clearly non-inferior to standard therapy insulin lispro, a rapid acting insulin, also combined with basal insulin, in reducing HbA1c levels in subjects with inadequately controlled Type 1 diabetes.

11 Jun 2010

Study identifies mechanism that interrupts normal p53 gene function leading to tumor development

The p53 gene has been a well-documented player in the prevention of tumors. It is considered the most frequently mutated gene in human tumors with more than half harboring p53 mutations (Bennett et al., 1999). These mutations often can be caused by disruption in normal p53 function.

11 Jun 2010

APP Pharmaceuticals to commence marketing of Oxaliplatin Injection in U.S

Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Oxaliplatin Injection (liquid) in the U.S. The U.S. Food and Drug Administration granted approval to market Oxaliplatin Injection in two dosage strengths to Fresenius Kabi Oncology Limited. APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. APP currently markets the lyophilized product, Oxaliplatin for Injection, 50 mg and 100 mg.

11 Jun 2010

Bevacizumab increases risk for proteinuria in cancer patients

Cancer patients treated with the chemotherapy agent bevacizumab (Avastin) may be at an increased risk of severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment. This conclusion stems from a study of more than 12,000 patients by Shenhong Wu, M.D., Ph.D., Principal Investigator, and colleagues at Stony Brook University Medical Center. Their findings are reported in online June 10 in the Journal of the American Society Nephrology (JASN).

11 Jun 2010

Phase 3 AVERROES clinical trial of apixaban for atrial fibrillation closes early due to clear evidence of efficacy

Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.

11 Jun 2010

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease. The FDA has the option of seeking the advice of one of its advisory committees as it reviews and decides whether to approve a new treatment. The committee voted unanimously that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and that safety of the proposed 0.5 mg dose justified approval.

11 Jun 2010

Remote monitoring and nurse case management combined improve health of Medicare beneficiaries with CHF

Chronic heart failure (CHF) is one of the most common causes of hospitalization for elderly Americans, and is also one of the nation's most costly conditions to treat.

10 Jun 2010

EC approves Nivestim for prevention of FN

Hospira announced today that the EC has approved Nivestim™ (filgrastim) for the prevention of FN, the most serious haematological toxicity that occurs as a result of cancer chemotherapy. Nivestim now has marketing authorisation in all EU member states. Nivestim is expected to reduce the cost of neutropenia treatment.

10 Jun 2010

FDA approves Endologix's expanded Powerlink stent graft product line

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its expanded offering of Powerlink® stent graft products. The approval covers 31 new sizes of Powerlink® main body bifurcated, proximal extension, and limb extension stent grafts that increase the system's addressable patient population by 5% to 10%.

10 Jun 2010

Actelion Pharmaceuticals announces availability of PAH Mobile Reference Guide

Actelion Pharmaceuticals US, Inc. is announcing the availability of the Pulmonary Arterial Hypertension Mobile Reference Guide, the first multimedia smart phone application that provides information on PAH disease, pathology, diagnosis, and treatment guidelines to healthcare professionals.

10 Jun 2010

Researchers develop new computer program for early diagnosis of Alzheimer's disease

Researchers of the University of Granada have developed a new computer program that allows early diagnosis of Alzheimer's disease through processed images. This new system has enhanced successful early diagnosis of Alzheimer's disease up to 90%, which is an important progress within this area of study.

10 Jun 2010

FDA grants Collegium Fast Track designation for COL-172 opioid formulation

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of COL-172 for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time.

10 Jun 2010

Raw and cooked gingers reduce pain associated with muscle injury by 24%: Reed's

Reed's, Inc., maker of the top-selling sodas in natural food stores nationwide, commented today on a recent study in The Journal of Medicine that both raw and cooked ginger reduce pain associated with muscle injury by about 24%, compared with placebo. The study was supported by the McCormick Science Institute.

10 Jun 2010

Neutralizing inhibitory molecules does not improve regeneration in damaged spinal axons

Neuroscientists at the University of California, San Diego School of Medicine have found that removing three key inhibitory molecules from myelin - the insulating material that surrounds nerve cell fibers - does not significantly boost the ability of injured spinal axons to regenerate and restore themselves to full function.

10 Jun 2010

MAP Pharmaceuticals to present new analyses from LEVADEX Phase 3 trial for acute migraine at 52nd AHS

MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.

10 Jun 2010

Spectranetics plans multi-center, randomized clinical trial program for in-stent restenosis

The Spectranetics Corporation today announced its clinical trial plans related to the treatment of in-stent restenosis (ISR) in arteries above the knee, which remains a major unsolved medical problem. There is no device currently cleared or approved by the FDA to treat ISR.

10 Jun 2010

Researchers validate effectiveness of genome sequencing process for hereditary genetic diseases

A research team led by Dr. Nada Jabado at the MUHC Research Institute and Dr. Jacek Majewski at McGill University has proven for the first time that it is possible to identify any genetic disease in record time thanks to a powerful and reliable exome sequencing method. The exome, a small part of the genome ((less than) 2%), is of crucial interest with regard to research on genetic diseases as it accounts for 85% of mutations.

10 Jun 2010

2010 Independence Expo to promote active living and independence for aged and disabled Americans

United Spinal Association presents the 2010 Independence Expo – Long Island, the region's premier lifestyle-enhancing Expo designed to promote active living and independence for all people with disabilities and aging Americans.

10 Jun 2010

Goodmans Interior Structures and Shore Memorial Hospital receives CEO Cancer Gold Standard accreditation

Goodmans Interior Structures and Shore Memorial Hospital have received CEO Cancer Gold Standard™ accreditation, recognizing commitment of these organizations to taking concrete actions to reduce the cancer risk of employees and their families through screenings, early detection, and healthy changes in lifestyle.

10 Jun 2010

Medical Condition News

Type 2 diabetes doubles risk of cancer in women

AFREZZA non-inferior to standard therapy insulin lispro in reducing HbA1c levels of Type 1 diabetics

Study identifies mechanism that interrupts normal p53 gene function leading to tumor development

APP Pharmaceuticals to commence marketing of Oxaliplatin Injection in U.S

Bevacizumab increases risk for proteinuria in cancer patients

Phase 3 AVERROES clinical trial of apixaban for atrial fibrillation closes early due to clear evidence of efficacy

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Remote monitoring and nurse case management combined improve health of Medicare beneficiaries with CHF

EC approves Nivestim for prevention of FN

FDA approves Endologix's expanded Powerlink stent graft product line

Actelion Pharmaceuticals announces availability of PAH Mobile Reference Guide

Researchers develop new computer program for early diagnosis of Alzheimer's disease

FDA grants Collegium Fast Track designation for COL-172 opioid formulation

Raw and cooked gingers reduce pain associated with muscle injury by 24%: Reed's

Neutralizing inhibitory molecules does not improve regeneration in damaged spinal axons

MAP Pharmaceuticals to present new analyses from LEVADEX Phase 3 trial for acute migraine at 52nd AHS

Spectranetics plans multi-center, randomized clinical trial program for in-stent restenosis

Researchers validate effectiveness of genome sequencing process for hereditary genetic diseases

2010 Independence Expo to promote active living and independence for aged and disabled Americans

Goodmans Interior Structures and Shore Memorial Hospital receives CEO Cancer Gold Standard accreditation

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News